Inicio・Lista de Acciones・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Cerrado

SectorSanidad

3.5 3.86

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.35

Máximo

3.5300000000000002

Métricas clave
By Trading Economics
Ingresos	4.1M -5.7M
BPA	-0.06
Empleados	34
EBITDA	-821K -6.5M

Dividendos
By Acuity
Próximas Ganancias	18 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	82M 314M
Apertura anterior	-0.36
Cierre anterior	3.5

Noticias sobre sentimiento de mercado

By Acuity

30%

70%

63 / 340 Clasificación en Healthcare

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 ago 2026, 23:22 UTC

Anavex Life Sciences Corp is trading lower in after-market hours with no specific news. The stock remains well above its 20-day moving average.

10 ago 2026, 19:46 UTC

Anavex Life Sciences is trading higher today, despite no specific news. Broader market sentiment is influenced by upcoming inflation data and Fed policy expectations.

7 ago 2026, 22:16 UTC

Anavex Life Sciences Corp is higher in after-market trading, continuing a trend of gains over the last seven sessions, despite no specific news identified.

6 ago 2026, 23:51 UTC

Anavex Life Sciences Corp is rising in after-market trading, reaching a high shortly after the market closed, despite no specific news driving the increase.

5 ago 2026, 21:01 UTC

Anavex Life Sciences shares fell in after-market trading, declining significantly despite being above its 20-day moving average and near the top of its one-month range.

4 ago 2026, 19:51 UTC

Anavex Life Sciences Corp is rising amid broader market strength and a decline in crude oil prices, despite pulling back from earlier session highs.

3 ago 2026, 20:02 UTC

News

Anavex Life Sciences Corp announces board changes amid a proxy fight, urging stockholders to reject PVG Asset Management's attempt to replace the board. Shares are higher.

30 jul 2026, 19:39 UTC

Event

Anavex Life Sciences reported Q2 earnings of -$0.06 per share, beating expectations. Shares remain higher since Wednesday's close despite pulling back from session highs.

29 jul 2026, 22:31 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, reflecting broader market gains following the Federal Reserve's decision to maintain interest rates.

28 jul 2026, 21:01 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, currently 1.45% below their 20-day moving average. No specific news was identified.

27 jul 2026, 20:07 UTC

Anavex Life Sciences Corp shares are higher during Monday's session, maintaining gains since Friday amid broader market trends and easing geopolitical tensions.

24 jul 2026, 17:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the move.

21 jul 2026, 19:51 UTC

Anavex Life Sciences is rising during Tuesday's session, recovering from a pre-market low. Broader market sentiment is supported by positive earnings from General Motors and Novartis.

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

63 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.